INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes

INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes

Abstract Background The INNODIA consortium has established a pan-European infrastructure using validated centres to prospectively evaluate clinical data from individuals with newly diagnosed type 1 diabetes combined with centralised collection of clinical samples to determine rates of decline in bet...

Full description

Bibliographic Details
Main Authors: David B. Dunger, Sylvaine F. A. Bruggraber, Adrian P. Mander, M. Loredana Marcovecchio, Timothy Tree, Piotr Jaroslaw Chmura, Mikael Knip, Anke M. Schulte, Chantal Mathieu, on behalf of the INNODIA consortium
Format: Article
Language:English
Published: BMC 2022-05-01
Series:Trials
Subjects:
Beta-cell function
C-peptide
Master protocol
Phase 2
Prevention
Trials
Online Access:https://doi.org/10.1186/s13063-022-06259-z

Internet

https://doi.org/10.1186/s13063-022-06259-z

Similar Items